Pelish Henry E. sold $261K of NUVL
Pelish Henry E. (Chief Scientific Officer) sold 2,111 shares of Nuvalent, Inc. (NUVL) at $123.81 ($0.26M total) on 2026-07-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price ($123.81/share), and that it occurred under a pre-arranged 10b5-1 plan; there is no accompanying company performance or guidance update.
Market read
Primarily a sentiment/positioning datapoint; not a fundamental catalyst.
What to watch
The disclosure does not state the insider’s rationale, and 10b5-1 plans are often used for regular liquidity needs, reducing interpretability.
Background
The article is an SEC Form 4 insider transaction for Nuvalent, Inc. (NUVL) by its Chief Scientific Officer.
Ticker impact
Nuvalent CSO Henry E. Pelish sold 2,111 shares for $261,362.91 under a pre-arranged 10b5-1 plan, filed July 10.
Likely minimal price impact; any reaction should be small and short-lived unless accompanied by other company-specific news.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operational or financial guidance.
Market effects
No clear sector read-across from a single planned insider sale at a biotech.
None indicated.
None indicated.
Counterpoint
Even planned 10b5-1 sales can coincide with internal expectations; traders may still treat it as a mild negative sentiment datapoint.
Key entities
- issuerNuvalent, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderPelish Henry E.
Chief Scientific Officer who sold 2,111 shares.
